Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Tumor Microenvironment”

288 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 288 results

Testing effectiveness (Phase 2)Study completedNCT03647839
What this trial is testing

Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer

Who this might be right for
Colorectal Cancer Metastatic
Australasian Gastro-Intestinal Trials Group 90
Not applicableLooking for participantsNCT06085781
What this trial is testing

Head and Neck MRI and Tumor Microenvironment Biomarkers

Who this might be right for
Squamous Cell Carcinoma of Head and Neck
University Health Network, Toronto 60
Not applicableLooking for participantsNCT07100405
What this trial is testing

TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma: Study on Efficacy and Immune Microenvironment

Who this might be right for
Hepatocellular Carcinoma
Fudan University 50
Testing effectiveness (Phase 2)UnknownNCT03844763
What this trial is testing

Targeting the Tumor Microenvironment in R/M SCCHN

Who this might be right for
Head and Neck Cancer
Gruppo Oncologico del Nord-Ovest 71
Early research (Phase 1)Ended earlyNCT03277209
What this trial is testing

To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas

Who this might be right for
Pancreas Cancer
Weill Medical College of Cornell University 2
Not applicableWithdrawnNCT02599909
What this trial is testing

Gut Microbiota in People With Hepatocellular Carcinoma (HCC)

Who this might be right for
Hepatocellular CarcinomaLiver CancerLiver Cell Caricinoma+1 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Active Not RecruitingNCT04121455
What this trial is testing

Glioblastoma Treatment With Irradiation and Olaptesed Pegol (NOX-A12) in MGMT Unmethylated Patients

Who this might be right for
Glioblastoma
TME Pharma AG 117
Testing effectiveness (Phase 2)Active Not RecruitingNCT05114421
What this trial is testing

Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients

Who this might be right for
High Grade Fallopian Tube Serous AdenocarcinomaHigh Grade Ovarian Serous AdenocarcinomaPeritoneal High Grade Serous Adenocarcinoma+3 more
M.D. Anderson Cancer Center 30
Not applicableStudy completedNCT06293612
What this trial is testing

Constructing a Multimodal Imaging System to Predict the Risk of Heterochronous Metastasis of Rectal Cancer

Who this might be right for
Locally Advanced Rectal CancerDistant Metastasis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 302
Early research (Phase 1)Study completedNCT04323202
What this trial is testing

Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H&N

Who this might be right for
Basal Cell Carcinoma of the Head and Neck
Case Comprehensive Cancer Center 13
Testing effectiveness (Phase 2)WithdrawnNCT06331585
What this trial is testing

Effect of Low-dose Radiotherapy on Tumor Immune Microenvironment in Oligometastases of NSCLC After Immunotherapy

Who this might be right for
Low-dose RadiotherapyTumor MicroenvironmentNon-Small Cell Lung Cancer
Hetian District People's Hospital
Not applicableUnknownNCT05677724
What this trial is testing

Single-cell RNA Sequencing Resolves the Regulatory Role of HBV on the Hepatocellular Carcinoma Immune Microenvironment

Who this might be right for
HBVPrimary Liver Cancer
Fubing Wang 20
Not applicableWithdrawnNCT05672082
What this trial is testing

Contribution of [18F]DPA-714 PET for Grading and Exploration of the Inflammatory Microenvironment of Glioma.

Who this might be right for
Glioma
Center Eugene Marquis
Testing effectiveness (Phase 2)Ended earlyNCT01703065
What this trial is testing

Cabozantinib in Men With Castration-Resistant Prostate Cancer

Who this might be right for
Adenocarcinoma of the ProstateCastration-resistant Prostate CancerRecurrent Prostate Cancer+2 more
University of Washington 9
Testing effectiveness (Phase 2)Active Not RecruitingNCT05827055
What this trial is testing

Proglumide and Chemotherapy for Metastatic Pancreatic Cancer

Who this might be right for
Metastatic Pancreatic Cancer
Georgetown University 30
Not applicableNot Yet RecruitingNCT06827639
What this trial is testing

In-depth Characterization of Circulating and Infiltrating Immune Subsets and Tumor Cells in Cancer Patients

Who this might be right for
Head and Neck CancerUrologic CancerLung Cancer+2 more
Assistance Publique Hopitaux De Marseille 640
Early research (Phase 1)Ended earlyNCT02309892
What this trial is testing

A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC

Who this might be right for
Non-Small Cell Lung Cancer
Helix BioPharma Corporation 14
Not applicableLooking for participantsNCT06536998
What this trial is testing

Exploring the Association of Imaging and Tumor Microenvironment in Liver Cancer Using Radiogenomic Approach（Radiogenomics-Liver）

Who this might be right for
Liver Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 150
Large-scale testing (Phase 3)UnknownNCT05698082
What this trial is testing

FOS Immunohistochemical Staining of Colorectal Cancer and Its Adjacent Tissues

Who this might be right for
Colorectal CancerMonkey Pox
xiaoliang Huang 120
Not applicableUnknownNCT05910710
What this trial is testing

Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

Who this might be right for
Triple Negative Breast CancerNeoadjuvant ChemotherapyPembrolizumab+1 more
Samsung Medical Center 50
Load More Results